- Home
- RDNW vs IKT Comparison
RDNW vs IKT Comparison
Compare RDNW & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDNW | IKT |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.9M | 240.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RDNW | IKT |
|---|---|---|
| Price | $7.16 | $1.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $6.50 | $5.00 |
| AVG Volume (30 Days) | 48.7K | ★ 1.0M |
| Earning Date | 05-08-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.01 | N/A |
| Revenue Next Year | $6.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.98 | $1.33 |
| 52 Week High | $7.20 | $2.37 |
Technical Indicators
Market Signals| Indicator | RDNW | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 62.57 | 55.41 |
| Support Level | $5.64 | $1.62 |
| Resistance Level | N/A | $1.88 |
| Average True Range (ATR) | 0.36 | 0.11 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 86.32 | 78.12 |
Price Performance
Historical ComparisonAbout RDNW RideNow Group Inc.
RideNow Group Inc is a USA-based online retailer that allows consumers and dealers both to Buy-Sell-Trade-Finance pre-owned motorcycles in an efficient, fast, transparent, and engaging experience.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.